Literature DB >> 8983610

Recurrence of hepatocellular carcinoma after surgery.

J Yamamoto1, T Kosuge, T Takayama, K Shimada, S Yamasaki, H Ozaki, N Yamaguchi, M Makuuchi.   

Abstract

A total of 386 patients who underwent complete resection of hepatocellular carcinoma over an 8-year period were assessed retrospectively for tumour recurrence. Some 219 (56.7 per cent) of the patients developed recurrence. Patients with a greater degree of cirrhosis showed a longer interval to recurrence; the median (range) interval until recurrence was 7.9 (1.8-84.2) months in patients with a normal liver, 13.4 (2.0-79.5) months in those with chronic hepatitis and 16.7 (1.5-73.1) months in those with cirrhosis. Intrahepatic recurrence was observed more frequently in either the same (26.4 per cent) or the adjacent (24.8 per cent) Healey segment than in the lobe contralateral to the primary tumour (17.8 per cent). The presence of portal venous invasion and/or intrahepatic metastasis, underlying liver cirrhosis and perioperative blood transfusion were determined to be independent predictors of recurrence by multivariate analysis. Because intrahepatic spread of hepatocellular carcinoma occurs in a segment-by-segment manner, surgeons should use an anatomically wide resection within the hepatic functional reserve.

Entities:  

Mesh:

Year:  1996        PMID: 8983610

Source DB:  PubMed          Journal:  Br J Surg        ISSN: 0007-1323            Impact factor:   6.939


  92 in total

1.  Ultrasound-guided microwave coagulation assists anatomical hepatic resection.

Authors:  Satoru Imura; Mitsuo Shimada; Tohru Utsunomiya; Yuji Morine; Tetsuya Ikemoto; Hiroki Mori; Jun Hanaoka; Shuichi Iwahashi; Yu Saito; Hidenori Miyake
Journal:  Surg Today       Date:  2011-11-12       Impact factor: 2.549

2.  Current status of therapy for hepatocellular carcinoma.

Authors:  Kathleen E Corey; Daniel S Pratt
Journal:  Therap Adv Gastroenterol       Date:  2009-01       Impact factor: 4.409

3.  Prognosis of Hepatocellular Carcinoma Patients Who Achieved Long-Term Recurrence-Free Survival After Curative Therapy: Impact of the ALBI Grade.

Authors:  Hajime Matsushima; Yuko Takami; Tomoki Ryu; Munehiro Yoshitomi; Masaki Tateishi; Yoshiyuki Wada; Hideki Saitsu
Journal:  J Gastrointest Surg       Date:  2018-05-07       Impact factor: 3.452

4.  Prognostic impact of anatomic resection for hepatocellular carcinoma.

Authors:  Kiyoshi Hasegawa; Norihiro Kokudo; Hiroshi Imamura; Yutaka Matsuyama; Taku Aoki; Masami Minagawa; Keiji Sano; Yasuhiko Sugawara; Tadatoshi Takayama; Masatoshi Makuuchi
Journal:  Ann Surg       Date:  2005-08       Impact factor: 12.969

5.  Radiofrequency ablation of hepatocellular carcinoma in difficult locations: Strategies and long-term outcomes.

Authors:  Wei Yang; Kun Yan; Gong-Xiong Wu; Wei Wu; Ying Fu; Jung-Chieh Lee; Zhong-Yi Zhang; Song Wang; Min-Hua Chen
Journal:  World J Gastroenterol       Date:  2015-02-07       Impact factor: 5.742

6.  Factors associated with disease survival after surgical resection in Chinese patients with hepatocellular carcinoma.

Authors:  Li Qiang; Li Huikai; Kelly Butt; P Peter Wang; Xishan Hao
Journal:  World J Surg       Date:  2006-03       Impact factor: 3.352

7.  Accelerated carcinogenesis following liver resection in chronically inflamed livers: A window of opportunity for treatment.

Authors:  Amir Sonnenblick; Tamar Zahavi
Journal:  Biomed Rep       Date:  2017-03-30

8.  Analysis of recurrence pattern and its influence on survival outcome after radiofrequency ablation of hepatocellular carcinoma.

Authors:  Kelvin K Ng; Ronnie T Poon; Chung-Mau Lo; Jimmy Yuen; Wai Kuen Tso; Sheung-Tat Fan
Journal:  J Gastrointest Surg       Date:  2007-09-15       Impact factor: 3.452

9.  Are gap junction gene connexins 26, 32 and 43 of prognostic values in hepatocellular carcinoma? A prospective study.

Authors:  I-Shyan Sheen; Kuo-Shyang Jeng; Po-Chuan Wang; Shou-Chuan Shih; Wen-Hsing Chang; Horng-Yuan Wang; Chung-Chu Chen; Li-Rung Shyung
Journal:  World J Gastroenterol       Date:  2004-10-01       Impact factor: 5.742

10.  The CD133+CD44+ precancerous subpopulation of oval cells is a therapeutic target for hepatocellular carcinoma.

Authors:  Yun-Wen Zheng; Tomonori Tsuchida; Taiki Shimao; Bin Li; Takanori Takebe; Ran-Ran Zhang; Yu Sakurai; Yasuharu Ueno; Keisuke Sekine; Naoto Ishibashi; Makiko Imajima; Takuji Tanaka; Hideki Taniguchi
Journal:  Stem Cells Dev       Date:  2014-06-26       Impact factor: 3.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.